• <em>APOC3</em> Interference for Familial Chylomicronaemia Syndrome
• A case of hypothyroidism and type 2 diabetes associated with type V hyperlipoproteinemia and eruptive xanthomas
• A case of V-type Hyperlipidemia with mycoses
• A possible contribution of decrease in free fatty acids to low serum triglyceride levels after diets supplemented with n-6 and n-3 polyunsaturated fatty acids
• Acute coronary syndrome and postprandial delayed hyperchylomicronemia
• Acute hyperlipidemic pancreatitis in pregnancy
• Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia
• Alterations of HDL subclasses in hyperlipidemia
• An investigation to determine the nutritional adequacy and individuals experience of a very low fat diet used to treat type V hypertriglyceridaemia
• Apolipoprotein E mutations, type V hyperlipoproteinaemia and diet
• Apolipoprotein E phenotype frequency in type II diabetic patients with different forms of hyperlipoproteinemia
• Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity
• Autoimmune hyperlipidemia in a child with autoimmune hepatitis
• Can we learn from our errors?
• Carotid intima-medial thickness in patients with severe hypertriglyceridemia
• Carotid intimamedia thickness in patients with severe hypertriglyceridemia
• Case report of one month and 15 days old baby with type V hyperlipoproteinemia (HLP)
• Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment
• Chylomicronaemia--current diagnosis and future therapies
• Cigarette smokers differ in their handling of natural (RRR) and synthetic (all rac) alpha-tocopherol: a biokinetic study in apoE4 male subjects
• Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study
• Clinical chemistry of atherosclerosis
• Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia
• Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia
• Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk
• Diabetic lipemia with maturity-onset diabetes of the young
• Diagnosis and management of type I and type V hyperlipoproteinemia
• Dietary fat clearance in type V hyperlipoproteinaemia secondary to a rare variant of human apolipoprotein E: the apolipoprotein E3 (Arg 136--&gt;Ser)
• Does Dietary Therapy for Hyperlipoproteinemia Type V Predispose to Premature Atherosclerosis?
• Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use
• Dyslipidaemia in a boy with recurrent abdominal pain, hypersalivation and decreased lipoprotein lipase activity
• Dyslipidemia and hyperuricemia: a cross-sectional study of residents in Wuhu, China
• Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia
• Effect of bezafibrate in isolated hypercholesterolemia and mixed hyperlipidemia on infarct risk (Stepwise Program for Individual Risk Identification and Therapy): an open multicenter study
• Effect of gemfibrozil on fatty acids in lipid fractions of plasma from patients with hypertriglyceridemia
• Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia
• Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia
• Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose
• Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)
• Efficacy and safety of combination therapy with simvastatin and fenofibrate for combined hyperlipidemia
• Eruptive xanthoma: Warning sign of systemic disease
• Eruptive Xanthomas Caused by Primary Type V Hyperlipoproteinemia
• Estimation of the prevalence of cholesteryl ester storage disorder in a cohort of patients with clinical features of familial hypercholesterolaemia
• Excessive hypertriglyceridemia and pancreatitis in a 17-year-old pregnant patient
• Familial combined hyperlipemia in childhood
• Familial type V hyperlipoproteinemia with hyper-remnant-like particle-cholesterol accompanied with apolipoprotein E3/E4 phenotype
• Fatty liver hepatitis and type 5 hyperlipoproteinemia in juvenile diabetes mellitus. Case report and review of the literature
• Genetic forms of dyslipidemia in children
• HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia
• High frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virus
• Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia
• Hyperlipidemia-induced pancreatitis in pregnancy. Successful long-term treatment by extracorporeal elimination of triglyceride-rich lipoproteins
• Hypertriglyceridemia: severe type V hyperlipidemia in a young woman
• Images in clinical medicine. Lipemia retinalis
• Interaction between variant apolipoproteins C-II and E that affects plasma lipoprotein concentrations
• Intra-individual variations in triglyceride and total cholesterol levels in serum in mixed hyperlipidemia
• Isolation and characterization of an apoA-II-containing lipoprotein (LP-A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipoproteinemia
• It's all connected
• L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study
• Lipemia retinalis associated with branch retinal vein occlusion
• Lipemia retinalis in an infant
• Lipemia retinalis: low-density lipoprotein apheresis improved the appearance of retinal vessels in a patient with type 5 hyperlipoproteinemia
• Lipid metabolism disorders--diagnosis and therapy in general practice. 8: Mixed hyperlipoproteinemias
• Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates
• Medical resource use and costs associated with chylomicronemia
• Metabolism of apolipoprotein B-100 and of triglyceride-rich lipoprotein particles in the absence of functional lipoprotein lipase
• Plasma sICAM levels during standard exercise test are higher in postmenopausal women with mixed hyperlipemia. sICAM level in postmenopausal women
• Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population
• Postprandial Hyperchylomicronemia and Thin-Cap Fibroatheroma in Nonculprit Lesions
• Prevention of recurrent acute pancreatitis in patients with severe hypertriglyceridemia: value of regular plasmapheresis
• Primary hyperlipoproteinemia type V
• Primary type V hyperlipidemia
• Primary type V hyperlipidemia
• Progression of severe atherosclerosis and increased arterial pulse pressure in the newly developed heritable mixed hyperlipidaemic rabbits
• Quantification of human plasma apolipoproteins C-I, C-II, and C-III by radioimmunoassays
• Reproducibility of fasting serum cholesterol and triglycerides in ambulatory patients with mixed hyperlipidemia
• Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia
• Scalp pain and hyperlipidaemia
• Severe acute pancreatitis associated with hyperlipidemia: report of two cases and review of the literature in Japan
• Severe dyslipidemia in pregnancy: The role of therapeutic apheresis
• Statin-fibrate combinations in patients with combined hyperlipedemia
• Tamponade of a bleeding pseudocyst with a fully covered metal stent
• The becoming of reactions of lipolysis in phylogenesis. The palmitic and oleic triglycerides as substrates. Insulin, condition of normolipemia and formation of hyper lipoproteinemia type IIb, IV and V
• The clinico-biochemical activity and tolerance of the hypolipidemic preparation lipanthyl
• The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling
• The fixed combination of pravastatin and fenofibrate: what can it provide?
• The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study
• The longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants
• The nephrotic syndrome in a female patient with hereditary hyperlipidemia type V
• The spleen as a storage pool in lipid metabolism
• The work-up for mixed hyperlipidemia: a case study
• Treatment of hyperlipidemia in the prevention of ischemic heart disease. A proposal for the unification of medical management. I and II
• Triacylglycerol composition of human endogenous lipoproteins
• Two cases with transient lipoprotein lipase (LPL) activity impairment: evidence for the possible involvement of an LPL inhibitor
• Type V hyperlipidemia associated with diabetic ketoacidosis
• Type V hyperlipidemia--an uncommon cause for pancreatitis
• Type V hyperlipoproteinemia in systemic lupus erythematosus
• Use of etofyllinclofibrate (Duolip Forte) in combined hyperlipidemia
• Variability of longitudinal triglyceride phenotype in patients heterozygous for pathogenic APOA5 variants
• Warts from minor trauma